BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.15.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Europabio
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20240124T120000
DTEND;TZID=Europe/Brussels:20240124T150000
DTSTAMP:20260623T231020
CREATED:20240109T104014Z
LAST-MODIFIED:20240116T095205Z
UID:7234-1706097600-1706108400@www.europabio.org
SUMMARY:EU pharmaceutical legislation - Europe’s biotech innovation in the balance?
DESCRIPTION:Event agenda \n\n\n\n12:00: Registration opens \n\n\n\n12:30: Panel starts \n\n\n\n13:45: Panel close and networking lunch \n\n\n\n15:00: Close \n\n\n\nConfirmed Speakers \n\n\n\nTomislav Sokol MEPMember SANT Committee\, European Parliament \n\n\n\nHilde StevensCo-director\, Institute for Interdisciplinary Innovation in Healthcare (I3H)\, ULB \n\n\n\nKristin ThompsonChief Operating Officer\, eureKARE \n\n\n\nVivian TsevelekiChief Operating Officer\, theraCell \n\n\n\nMore to be announced soon \n\n\n\nIntroduction \n\n\n\nIn April 2023\, the European Commission adopted a proposal for a new Directive and a new Regulation\, aimed at revising and replacing the existing General Pharmaceutical Legislation (GPL). The proposal focuses on modernising the pharmaceutical sector with a patient-centred approach\, while also fully supporting an innovative and competitive industry. \n\n\n\nThrough the proposal\, the EU aims to offer an attractive and innovation-friendly environment for research\, development\, and production of medicines in Europe. The EU plans to create this environment by promoting world-class innovation\, governed by stable and consistent rules that keep pace with innovation and which increase competitiveness while reducing red tape and costs. \n\n\n\nOne of the sectors impacted by the proposal is that of biotechnology\, which has been instrumental in the discovery and development of therapies\, diagnostics\, vaccines and\, most importantly\, advanced medicines. These ‘next generation medicines’ are delivered through a complex and interdependent biotechnology ecosystem\, where companies of all sizes contribute to establishing a pathway to patients. \n\n\n\nJoin this Euractiv Hybrid Conference to discuss Europe’s biotech innovation in light of the EU’s reform of the General Pharmaceutical Legislation.  \n\n\n\nQuestions to be discussed include: \n\n\n\n\nHow can Europe’s biotechnology industry maintain its competitiveness in the global medical market?\n\n\n\nHow can we establish a framework that fosters the growth of small biotech innovators?\n\n\n\nWhat are the reactions of investors to the challenges faced by small biotech companies\, and how do these reactions influence the trajectory of innovation in the biotech industry?\n\n\n\nWhat strategies can be employed to establish a successful innovation pathway for biotech companies\, while considering and aligning with the objectives of the reformed GPL?
URL:https://www.europabio.org/event/eu-pharmaceutical-legislation-europes-biotech-innovation-in-the-balance/
CATEGORIES:All,EuropaBio,External,Healthcare Biotech,SME Platform
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2024/01/EuropaBio.png
END:VEVENT
END:VCALENDAR